SPEED OF LIFE

– Building a strong and sustainable Life science sector – together

 

Company representatives from the prosperous Life science industry, will share their journey, success strategies and examples concerning entrepreneurship. Business leaders, researchers, marketers, economists, business developers and other experts jointly describe the environment their companies operate in, what drives them and what challenges they face.
Listen, be inspired, learn and take the insights to your company and gain value today!

New episodes will be published every second week from May 2021. In addition, to give you even more insight in the everyday life of the entrepreneurs, our LinkedIn account will be ”hijacked” by the company presented, during the week of promotion. Stay up to date by following STUNS Life science on LinkedIn.

This podcast is sponsored through the project BIO-X Accelerate led by STUNS Life science with the goal of promoting a sustainable growth of the Life science industry in East Middle Sweden. The project is funded by European Regional Development Fund (ERDF), Region Uppsala and STUNS Life Science.

We look forward to sharing value with you. 

Podcast series

Celluminova AB

Near-instant detection of live stem cells

– The Biomarker Gliostem® will help neurosurgeons distinguish between healthy and cancerous tissue during brain tumor surgery

Celluminova specializes in developing new tools for stem cell research, including cancer stem cells. The patented biomarker GlioStem is intended for the detection and visualization of stem cell-like cells in brain tumors. Today, there are no products on the market that target stem cell-like cells in these tumors. The goal for GlioStem is to be used during surgery to completely remove tumor tissue and thereby lead to increased patient survival and quality of life.

Read more about Celluminova

Gradientech AB

Precision medicine for a sustainable world

Gradientech is a Swedish diagnostics company dedicated to supporting the modern microbiology lab with state-of-the-art solutions that facilitate the testing of time-critical sepsis samples.

Gradientech is currently developing the in vitro diagnostic QuickMIC® system, a new platform for ultra-rapid testing of antibiotic resistance. The system is expected to become the most rapid solution for determining the appropriate antibiotic treatment of sepsis patients. Rapid testing of antibiotic resistance is vital for increasing sepsis patient survival, reducing healthcare costs, and lowering the spread of antibiotic resistance.

Read more about Gradientech

PU Sensor AB

PU sensor enables prevention of pressure ulcers

PU sensor has developed a method for evaluating a patient’s physiological condition regarding blood flow at pressure and thereby anticipate the risk of pressure ulcer and prevent it from appearing.

Pressure ulcer (bedsore) is a both painful and dangerous but unfortunately common medical injury. Among health care related injuries, pressure ulcers are one of the most burdensome both economically and when it comes to human suffering, OECD reports. Pressure ulcers arise in all age groups and all over the world. Cost increase with ulcer severity because the time to heal is longer and the incidence of complication is higher in more severe cases. The cost of treating pressure ulcer is likely to increase in the future as the population ages.

Read more about PU Sensor

Ilya Pharma AB

Ilya Pharma is developing next-generation immunotherapies to treat wounds in skin and mucosa

The ILP-technology is based on deploying chemokines, which until now have been regarded too unstable to be suitable as therapeutics. Ilya Pharma has overcome this problem by letting live lactic acid bacteria produce and deliver the human therapeutic chemokines on site in wounds in skin or e.g in the intestine acting like small bioreactors. In addition to the documented biologic and clinical effect on accelerating the healing and recovery, it is a very cost efficient system to deliver drugs, compared to cell therapies and other traditional biologics.

Read more about Ilya Pharma

Astrego AB

Providing the antibiotic resistance profile at the point of care

The increase of antibiotic resistance is a global threat to human health. It is due to over- and miss-use of antibiotics, as a result of that doctors currently need to prescribe antibiotics before they know the resistance profile of the bacteria.

Astrego’s technology provides such a resistance profile in 30 min and therfore allows prescription of effective,  non-broad spectrum, antibiotics at the point-of-care. Astrego’s first product targets urinary tract infection, which affects 100 milj women each year, and represents 15% of the antibiotic use in human medicine.

Read more at astrego.se

BioReperia AB

BioReperia’s revolutionary ZTX-Platform and related products

BioReperia helps every cancer patient to get the most effective treatment available, for their specific disease.

BioReperia has developed a unique zebrafish tumor xenograft (ZTX™) platform that provides functional in-vivo data to evaluate treatment efficacy for tumor regression and metastasis inhibition in only 5 days.

Our goal is to increase the speed and accuracy of preclinical drug development and clinical cancer treatment, enabling researchers and clinicians to select the drugs/drug candidates with the highest potential to succeed in less time.

Read more at bioreperia.com

Coming next:

 

Week 40 Senzime AB

Week 42 Immuneed AB

Week 45 Deversify AB

Week 47 Stardots AB

Week 49 Special Episode 

New podcasts are published regularly. Follow us on LinkedIn to stay up to date
Picture: Logo of the European Regional Development Fund